08:22 AM EDT, 05/20/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Tuesday said it has begun dosing a patient with 120 mg of its lead compound tuspetinib as part of a triple drug therapy to treat patients newly diagnosed with acute myeloid leukemia (AML).

The safety review committee overseeing the Phase 1/2 Tuscany trial approved escalating the tuspetinib dosage from 80 mg to 120 mg based on its favorable review of safety and efficacy data from patients in the first two cohorts of the trial.

No significant safety concerns or dose limiting toxicities have been reported in the trial, Aptose confirmed. Patients treated in the 40 mg and 80 mg dose cohorts remain on study while enrollment is open for the 120 mg dose cohort.

The company will be presenting updated data in an oral presentation at the European Hematology Association Congress being held June 12-15, 2025, in Milan, Italy.